Pharma Resources Co., Ltd. (301230)
XSHE XSHE Primary Summary
301230 Chart
People also search for
Pharma Resources Co., Ltd. (301230) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pharma Resources Co., Ltd. ever had a stock split?
Pharma Resources Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Ping Chen Ph.D. CEO | XSHE Exchange | CNE1000065Q9 ISIN |
| CN Country | 1,004 Employees | 13 Jan 2026 Last Dividend | 16 Jul 2026 Last Split | - IPO Date |
Overview
PharmaResources (Shanghai) Co., Ltd. is a multifaceted pharmaceutical company based in Shanghai, China, encapsulating a comprehensive range of services within the pharmaceutical sector. Established in 2007, the company has positioned itself as a prominent Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), and Contract Manufacturing Organization (CMO) specializing in the realm of drug discovery. Its strategic operations within China's bustling pharmaceutical landscape enable PharmaResources to offer an integrated service platform for small molecule drug development and manufacturing, thereby catering to the burgeoning needs of the pharmaceutical industry globally.
Products and Services
- Preclinical Services
- API Manufacturing
- Key Intermediates Manufacturing
- Small Molecule Medicines Manufacturing
The company provides a suite of preclinical services designed to assist in the early stages of drug development. These services focus on the discovery and optimization of potential drug candidates, enabling streamlined progression through the drug development pipeline. By leveraging advanced technologies and expert scientific acumen, PharmaResources facilitates efficient and effective preclinical testing, encompassing safety, efficacy, and pharmacokinetic evaluations.
PharmaResources specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs), which are critical components in drug formulation. Their manufacturing capabilities encompass a wide range of APIs, catering to diverse therapeutic areas. By adopting stringent quality control measures and leveraging state-of-the-art manufacturing technologies, the company ensures the production of high-quality APIs crucial for the development of effective and safe pharmaceutical products.
The creation of key intermediates for drug synthesis represents another core service offered by PharmaResources. These intermediates are pivotal in the synthesis of APIs and play a crucial role in the overall drug manufacturing process. The company's expertise in synthesizing these intermediates not only ensures the seamless production of APIs but also enhances the efficiency and reliability of the drug development and manufacturing lifecycle.
PharmaResources extends its capabilities to the manufacturing of small molecule related medicines, which form the backbone of many therapeutic regimens. Small molecules are favored in drug development for their ability to modulate biological targets effectively. The company's manufacturing services in this domain encompass the production of a wide spectrum of small molecule drugs, adhering to the highest standards of quality, safety, and efficacy.
